Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Biocryst Pharmaceuticals Inc shares valued at $595,868 were sold by HEGGIE THERESA on Aug 13 ’25. At $8.51 per share, HEGGIE THERESA sold 70,000 shares. The insider’s holdings dropped to 65,352 shares worth approximately $0.55 million following the completion of this transaction.
Also, HEGGIE THERESA purchased 70,000 shares, netting a total of over 595,871 in proceeds.
Before that, Hutson Nancy J had sold 7,000 shares from its account. In a trade valued at $52,780, the Director traded Biocryst Pharmaceuticals Inc shares for $7.54 each. Upon closing the transaction, the insider’s holdings decreased to 7,000 shares, worth approximately $0.73 million.
As published in their initiating research note from Cantor Fitzgerald on April 29, 2025, Biocryst Pharmaceuticals Inc [BCRX] has been an Overweight and the price target has been revised to $20. Analysts at Wedbush started covering the stock with ‘”an Outperform”‘ outlook in a report released in late February. Earlier on September 18, 2023, RBC Capital Mkts upgraded its rating. Their new recommendation was “an Outperform” for BCRX stock which previously was a “a Sector perform”.
Analyzing BCRX Stock Performance
The stock’s lowest price that day was $8.32, but it reached a high of $8.45 in the same session. During the last five days, there has been a drop of approximately -0.83%. Over the course of the year, Biocryst Pharmaceuticals Inc shares have jumped approximately 6.62%. Shares of the company reached a 52-week high of $11.31 on 06/04/25 and a 52-week low of $6.01 on 04/10/25.
Support And Resistance Levels for Biocryst Pharmaceuticals Inc (BCRX)
According to the 24-hour chart, there is a support level at 8.32, which, if violated, would cause prices to drop to 8.25. In the upper region, resistance lies at 8.45. The next price resistance is at 8.51. RSI (Relative Strength Index) is 46.08 on the 14-day chart, showing neutral technical sentiment.
Is Biocryst Pharmaceuticals Inc subject to short interest?
Stocks of Biocryst Pharmaceuticals Inc saw a sharp steep in short interest on 2025-07-31 dropping by -1.34 million shares to 25.88 million. Data from Yahoo Finance shows that the short interest on 2025-06-30 was 27.22 million shares. A decline of -5.18% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 8.05 of the overall float, the days-to-cover ratio (short ratio) decline to 8.05.
Which companies own the most shares of Biocryst Pharmaceuticals Inc (BCRX)?
In terms of Biocryst Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 16 in the next 12 months, up nearly 90.93% from the previous closing price of $8.38. Analysts anticipate Biocryst Pharmaceuticals Inc stock to reach 25 by 2025, with the lowest price target being 7. In spite of this, 13 analysts ranked Biocryst Pharmaceuticals Inc stock as Buy at the end of 2025. On August 04, 2023, Jefferies assigned a price target of “a Buy” to the stock and upgraded coverage with a $11.
